Petropolis

Researchers are evaluating the combination of sonrotoclax plus zanubrutinib compared with zanubrutinib plus placebo in adults with relapsed or refractory mantle cell lymphoma MCL. This Phase 3 randomized, double-blind study aims to compare how well these treatments work and assess their safety in this patient population. The study is sponsored by BeOne Medicines and focuses on patients who have previously received 1 to 5 prior systemic therapies including anti-CD20 monoclonal antibody or chemoimmunotherapy. Participants will receive either sonrotoclax plus zanubrutinib or placebo plus zanubrutinib, both administered orally. The study has two groups one receiving the combination of sonrotoclax and zanubrutinib, and the other receiving zanubrutinib with placebo. Treatment continues as per protocol, and the study includes detailed assessments of response and safety over time. During the study, participants will be monitored for progression-free survival as the primary outcome, assessed by an independent review committee over approximately 41 months. Secondary outcomes include overall survival, response rates, duration of response, health-related quality of life, and adverse events up to around 58 months. Regular evaluations will be conducted to assess disease status, quality of life, and safety throughout the trial, which is planned to complete by 2032.

Researchers are evaluating BGB-43395, a selective CDK4 inhibitor, as a single treatment and in combination with fulvestrant, letrozole, or elacestrant for participants with hormone receptor positive HR and HER2-negative breast cancer as well as other advanced solid tumors. This phase 1a1b study aims to determine the recommended dosing of BGB-43395 while assessing safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity. The study has multiple parts Phase 1a involves dose escalation with increasing doses of BGB-43395 alone or combined with the other drugs to evaluate safety and tolerability. Selected dose levels then move to Phase 1a safety expansion cohorts with combinations in HRHER2- breast cancer. Phase 1b tests the recommended dose for expansion RFDE of BGB-43395 combined with fulvestrant or letrozole in HR breast cancer, including a subgroup receiving an anti-diarrheal agent to prevent side effects. Treatments are administered orally or by injection depending on the drug. Participants undergo regular monitoring for adverse events, dose tolerability, and response rates over up to approximately 60 months. Blood samples are taken to measure drug levels and metabolism during treatment cycles lasting 28 days. Researchers assess tumor response, disease control, and progression-free survival. The study also tracks safety events and collects pharmacokinetic data to guide dosing. Participation may last up to several years depending on treatment duration and follow-up assessments.